With the accelerated approval on January 6, 2023 for early Alzheimer's disease, Eisai/Biogen's Leqembi became only the second approved disease-modifying therapy (DMT) for early Alzheimer's...
C2N Diagnostics, a leader in advanced brain health diagnostics, announced the presentation of two research studies at the AD/PD 2023 International Conference on Alzheimer’s...
Cognito Therapeutics, announced neuroimaging results evaluating the effects of the company’s non-invasive neuromodulation medical device, which delivers proprietary gamma frequency light and sound stimulation in...
Sonde Health, a health technology company committed to bringing accessible health monitoring to everyone, in conjunction with the Massachusetts General Hospital (MGH) Frontotemporal Disorders...
Linus Health, a digital health company focused on transforming brain health, announced that the Goizueta Institute Emory Brain Health and The Seavey Clinic at...
